Effect of Eriodictyol on the Development of Atopic Dermatitis-Like Lesions in ICR Mice

Atopic dermatitis (AD) is a chronic, allergic, and inflammatory skin disease associated with eczema and dermatitis symptoms. Our previous studies have reported that eriodictyol extract inhibits immunoglobulin E (IgE)/Ag-induced type I hypersensitivity by suppressing the activation of proinflammatory...

Full description

Saved in:
Bibliographic Details
Published in:Biological & pharmaceutical bulletin 2013/08/01, Vol.36(8), pp.1375-1379
Main Authors: Park, Sae-Jin, Lee, Yong-Hyeon, Lee, Kwang Ho, Kim, Tack-Joong
Format: Article
Language:English
Subjects:
Animals
Anti-Allergic Agents - therapeutic use
Anti-Inflammatory Agents - therapeutic use
atopic dermatitis
Behavior, Animal - drug effects
Dermatitis, Atopic - blood
Dermatitis, Atopic - chemically induced
Dermatitis, Atopic - drug therapy
Dermatitis, Atopic - pathology
Dinitrochlorobenzene
eriodictyol
Flavanones - therapeutic use
Immunoglobulin E - blood
Male
Mice
Mice, Inbred ICR
Pruritus - blood
Pruritus - chemically induced
Pruritus - drug therapy
Pruritus - pathology
scratching behavior
Skin - pathology
skin severity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Atopic dermatitis (AD) is a chronic, allergic, and inflammatory skin disease associated with eczema and dermatitis symptoms. Our previous studies have reported that eriodictyol extract inhibits immunoglobulin E (IgE)/Ag-induced type I hypersensitivity by suppressing the activation of proinflammatory cytokines, such as interleukin-4 (IL-4), and the expression of ceramide kinase. In this study, we investigated the inhibitory effect of eriodictyol on 2,4-dinitrochlorobenzene (DNCB)-induced AD-like skin lesions in ICR mice. Treatment with 2 mg/mL eriodictyol for DNCB-induced AD-like skin lesions in ICR mice improved scratching behavior and skin severity score. Histological analysis demonstrated that thickening of the skin lesions were significantly reduced in the eriodictyol-treated group. Also, eriodictyol suppressed the DNCB-mediated elevation of IgE serum levels. These results suggest that eriodictyol may be a potential therapeutic resource for AD and an adjunctive agent to control itchiness in AD.
ISSN:0918-6158
1347-5215
DOI:10.1248/bpb.b13-00296